Search

Your search keyword '"Wagner, Ralf"' showing total 1,459 results
Start Over Author "Wagner, Ralf"
1,459 results on '"Wagner, Ralf"'

10. Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection

Author

Ahmed, Mohamed I.M., Einhauser, Sebastian, Peiter, Clemens, Senninger, Antonia, Baranov, Olga, Eser, Tabea M., Huth, Manuel, Olbrich, Laura, Castelletti, Noemi, Rubio-Acero, Raquel, Carnell, George, Heeney, Jonathan, Kroidl, Inge, Held, Kathrin, Wieser, Andreas, Janke, Christian, Hoelscher, Michael, Hasenauer, Jan, Wagner, Ralf, and Geldmacher, Christof

Published
2024
Full Text
View/download PDF

12. Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells

Author

Albanese, Manuel, Chen, Hong-Ru, Gapp, Madeleine, Muenchhoff, Maximilian, Yang, Hsiu-Hui, Peterhoff, David, Hoffmann, Katja, Xiao, Qianhao, Ruhle, Adrian, Ambiel, Ina, Schneider, Stephanie, Mejías-Pérez, Ernesto, Stern, Marcel, Wratil, Paul R., Hofmann, Katharina, Amann, Laura, Jocham, Linda, Fuchs, Thimo, Ulivi, Alessandro F., Besson-Girard, Simon, Weidlich, Simon, Schneider, Jochen, Spinner, Christoph D., Sutter, Kathrin, Dittmer, Ulf, Humpe, Andreas, Baumeister, Philipp, Wieser, Andreas, Rothenfusser, Simon, Bogner, Johannes, Roider, Julia, Knolle, Percy, Hengel, Hartmut, Wagner, Ralf, Laketa, Vibor, Fackler, Oliver T., and Keppler, Oliver T.

Published
2024
Full Text
View/download PDF

13. Assessing immunogenicity barriers of the HIV-1 envelope trimer

Author

Maliqi, Liridona, Friedrich, Nikolas, Glögl, Matthias, Schmutz, Stefan, Schmidt, Daniel, Rusert, Peter, Schanz, Merle, Zaheri, Maryam, Pasin, Chloé, Niklaus, Cyrille, Foulkes, Caio, Reinberg, Thomas, Dreier, Birgit, Abela, Irene, Peterhoff, David, Hauser, Alexandra, Kouyos, Roger D., Günthard, Huldrych F., van Gils, Marit J., Sanders, Rogier W., Wagner, Ralf, Plückthun, Andreas, and Trkola, Alexandra

Published
2023
Full Text
View/download PDF

17. Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults

Author

Prelog, Martina, Jeske, Samuel D., Asam, Claudia, Fuchs, Andre, Wieser, Andreas, Gall, Christine, Wytopil, Monika, Mueller-Schmucker, Sandra M., Beileke, Stephanie, Goekkaya, Mehmet, Kling, Elisabeth, Geldmacher, Christof, Rubio-Acero, Raquel, Plank, Michael, Christa, Catharina, Willmann, Annika, Vu, Martin, Einhauser, Sebastian, Weps, Manuela, Lampl, Benedikt M.J., Almanzar, Giovanni, Kousha, Kimia, Schwägerl, Valeria, Liebl, Bernhard, Weber, Beatrix, Drescher, Johannes, Scheidt, Jörg, Gefeller, Olaf, Messmann, Helmut, Protzer, Ulrike, Liese, Johannes, Hoelscher, Michael, Wagner, Ralf, Überla, Klaus, and Steininger, Philipp

Published
2024
Full Text
View/download PDF

25. Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”

Author

Kibler, Karen V, Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L, Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C, Tomaras, Georgia D, Roederer, Mario, Foulds, Kathryn E, Forthal, Donald N, Seaman, Michael S, Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D, Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L, Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, and Jacobs, Bertram L

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Good Health and Well Being, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

Volume 93, no. 3, e01513-18, 2019, https://doi.org/10.1128/JVI.01513-18. The article was originally published on 17 January 2019 with a standard copyright line (“© 2019 American Society for Microbiology. All Rights Reserved.”). We elected to pay for open access for the article after publication, necessitating replacement of the original copyright line with “© 2019 Kibler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.” This change was made to the online version of the article on 21 August 2019.

Published
2019

26. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry

Author

Valero, Julián, Civit, Laia, Dupont, Daniel M., Selnihhin, Denis, Reinert, Line S., Idorn, Manja, Israels, Brett A., Bednarz, Aleksandra M., Bus, Claus, Asbach, Benedikt, Peterhoff, David, Pedersen, Finn S., Birkedal, Victoria, Wagner, Ralf, Paludan, Søren R., and Kjems, Jørgen

Published
2021

33. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Author

Kibler, Karen V, Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L, Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C, Tomaras, Georgia D, Roederer, Mario, Foulds, Kathryn E, Forthal, Donald N, Seaman, Michael S, Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D, Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L, Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, and Jacobs, Bertram L

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related (AIDS), Biotechnology, Prevention, Immunization, HIV/AIDS, Vaccine Related, Infectious Diseases, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Animals, Antibodies, Neutralizing, CD4-Positive T-Lymphocytes, HIV Antibodies, HIV Antigens, HIV Infections, HIV-1, Humans, Macaca mulatta, Male, Vaccination, Vaccinia virus, Viral Vaccines, Virus Replication, env Gene Products, Human Immunodeficiency Virus, Gag-Pol-Nef, HIV, NYVAC, NYVAC-KC, T cell response, antibody responses, gp140, nonhuman primates, vaccines, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia virus strain NYVAC. NYVAC is a vector that has been used in many previous clinical studies but is replication deficient. Here, we report a side-by-side comparison of replication-restricted NYVAC and replication-competent NYVAC-KC in a nonhuman primate study, which utilized a prime-boost regimen similar to that of RV144. NYVAC-C and NYVAC-C-KC express the HIV-1 antigens gp140, and Gag/Gag-Pol-Nef-derived virus-like particles (VLPs) from clade C and were used as the prime, with recombinant virus plus envelope protein used as the boost. In nearly every T and B cell immune assay against HIV-1, including neutralization and antibody binding, NYVAC-C-KC induced a greater immune response than NYVAC-C, indicating that replication competence in a poxvirus may improve upon the modestly successful regimen used in the RV144 clinical trial.IMPORTANCE Though the RV144 phase III clinical trial showed promise that an effective vaccine against HIV-1 is possible, a successful vaccine will require improvement over the vaccine candidate (ALVAC) used in the RV144 study. With that goal in mind, we have tested in nonhuman primates an attenuated but replication-competent vector, NYVAC-KC, in direct comparison to its parental vector, NYVAC, which is replication restricted in human cells, similar to the ALVAC vector used in RV144. We have utilized a prime-boost regimen for administration of the vaccine candidate that is similar to the one used in the RV144 study. The results of this study indicate that a replication-competent poxvirus vector may improve upon the effectiveness of the RV144 clinical trial vaccine candidate.

Published
2019

34. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Author

Asbach, Benedikt, Kibler, Karen V, Köstler, Josef, Perdiguero, Beatriz, Yates, Nicole L, Stanfield-Oakley, Sherry, Tomaras, Georgia D, Kao, Shing-Fen, Foulds, Kathryn E, Roederer, Mario, Seaman, Michael S, Montefiori, David C, Parks, Robert, Ferrari, Guido, Forthal, Donald N, Phogat, Sanjay, Tartaglia, James, Barnett, Susan W, Self, Steven G, Gottardo, Raphael, Cristillo, Anthony D, Weiss, Deborah E, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L, Esteban, Mariano, Jacobs, Bertram L, Pantaleo, Giuseppe, and Wagner, Ralf

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Prevention, Vaccine Related, HIV/AIDS, Biotechnology, Immunization, Rare Diseases, Vaccine Related (AIDS), Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Animals, Antibodies, Neutralizing, HIV Antibodies, HIV Antigens, HIV Infections, HIV-1, Humans, Macaca mulatta, Male, Poxviridae, T-Lymphocytes, Vaccination, Vaccines, DNA, Vaccinia virus, Viral Vaccines, Virus Replication, DNA vaccine, Gag-Pol-Nef, NYVAC, NYVAC-KC, T cell responses, antibody responses, gp140, human immunodeficiency virus, nonhuman primates, vaccine, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different delivery modalities, three different poxvirus boost regimens were compared. Three groups of rhesus macaques were each primed with the same DNA vaccine encoding Gag, Pol, Nef, and gp140. The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved replication competence in human cells, termed NYVAC-KC. The latter was administered either by scarification or intramuscularly. Finally, macaques were boosted with adjuvanted gp120 protein to enhance humoral responses. The regimen elicited very potent CD4+ and CD8+ T cell responses in a well-balanced manner, peaking 2 weeks after the boost. T cells were broadly reactive and polyfunctional. All animals exhibited antigen-specific humoral responses already after the poxvirus boost, which further increased following protein administration. Polyclonal reactivity of IgG antibodies was highest against HIV-1 clade C Env proteins, with considerable cross-reactivity to other clades. Substantial effector functional activities (antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated virus inhibition) were observed in serum obtained after the last protein boost. Notably, major differences between the groups were absent, indicating that the potent priming induced by the DNA vaccine initially framed the immune responses in such a way that the subsequent boosts with NYVAC and protein led only to an increase in the response magnitudes without skewing the quality. This study highlights the importance of selecting the best combination of vector systems in heterologous prime-boost vaccination regimens.IMPORTANCE The evaluation of HIV vaccine efficacy trials indicates that protection would most likely correlate with a polyfunctional immune response involving several effector functions from all arms of the immune system. Heterologous prime-boost regimens have been shown to elicit vigorous T cell and antibody responses in nonhuman primates that, however, qualitatively and quantitatively differ depending on the respective vector systems used. The present study evaluated a DNA prime and poxvirus and protein boost regimen and compared how two poxvirus vectors with various degrees of replication capacity and two different delivery modalities-conventional intramuscular delivery and percutaneous delivery by scarification-impact several immune effectors. It was found that despite the different poxvirus boosts, the overall immune responses in the three groups were similar, suggesting the potent DNA priming as the major determining factor of immune responses. These findings emphasize the importance of selecting optimal priming agents in heterologous prime-boost vaccination settings.

Published
2019

41. Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages

Author

Neckermann, Patrick, primary, Mohr, Madlen, additional, Billmeier, Martina, additional, Karlas, Alexander, additional, Boilesen, Ditte R., additional, Thirion, Christian, additional, Holst, Peter J., additional, Jordan, Ingo, additional, Sandig, Volker, additional, Asbach, Benedikt, additional, and Wagner, Ralf, additional

Published
2024
Full Text
View/download PDF

43. Intuitive and Deliberative Decision-Making in Negotiations

Author

Zulauf Katrin and Wagner Ralf

Subjects
decision-making, deliberation, intuition, negotiation, preference for intuition, and deliberation pid, Business, HF5001-6182
Abstract

This study departs from common conjecture by challenging the preference for deliberation or intuition, or both, in negotiations. In contrast to prior negotiation studies considering judgment precision, this study builds on underlying personality traits. Therefore, the findings are valid beyond the experimental context. This study conceptualizes and experimentally tests the impact of preference for intuitive and deliberate decision-making during negotiations in Chinese, German, and Polish cultures. Contrasting an emotional with a neutral setting, the paper evaluates the impact preference for intuition and deliberation have on negotiation outcome. The results challenge the frequent assumption made in negotiation analysis: Deliberative negotiators are superior.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results